In a parallel development, already in 2024 both Novo Nordisk and Lilly dropped BMI ranges from their respective FDA labels for Wegovy and Zepbound, just leaving the reference to obese and overweight patients
For context, in one study of 175 people with overweight or obesity, participants taking semaglutide: Lost an average of 15 pounds (about 6% of their body weight) within three months Lost an average of 27 pounds (about 11% of their body weight) after six months Recommended lifestyle changes during GLP-1 therapy GLP-1 medications can boost weight loss by increasing satiety and reducing food cravings
Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
The mechanisms responsible for weight loss are in part due to GLP-1 RA effects on appetite and satiety control centers in the central nervous system [60]
Comprehensive Wellbeing By week seven or eight, improvements extend beyond isolated benefits into a general sense of enhanced wellbeing
many patients transition from injections to oral maintenance once levels are corrected and absorption is adequate